Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

A Corrigendum on
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

by Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J and Choueiri TK (2023) Front. Oncol. 13:1223282. doi: 10.3389/fonc.2023.1223282

In the published article, there was an error in the legend for Figure 3 and Supplementary Table 1 as published. Clarification that objective response rates and complete response rates were calculated based on the number of patients in each listed subgroup was omitted. The corrected legend of both appears below.

Figure 3

Figure 3 ORR^a and Odds Ratios for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment in Subgroups of Interest. ^aAs assessed by IRC per RECIST v1.1. ^bPercents were calculated based on listed subgroups. CI, confidence interval; CR, complete response; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IRC, independent review committee; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1; S, sunitinib.

“^aAs assessed by IRC per RECIST v1.1. ^bPercents were calculated based on listed subgroups.”

In the published article, there was an error in Figure 3 and Supplementary Table 1 as published. For both, percentages in the “complete response” column were incorrectly calculated as the number of patients with a complete response in each subgroup divided by all patients in the respective treatment arm (n=355 for lenvatinib + pembrolizumab; n=357 for sunitinib) instead of being divided by the number of patients in each applicable subgroup.

The corrected Figure 3 and its captions (also corrected per the above to “^aAs assessed by IRC per RECIST v1.1. ^bPercents were calculated based on listed subgroups.”) appear below.

The text did not account for the revisions made to the complete response rate mentioned above.

A correction has been made to Section 3.2.3 (Objective response), paragraph 2. This sentence previously stated:

“As expected, the rates of CRs were higher in patients without baseline bone metastases or baseline liver metastases, in patients who had baseline lung metastases, and in patients who had a prior nephrectomy. While the number of patients with sarcomatoid features was small, the rates of CRs in patients without sarcomatoid features was higher than those of patients with sarcomatoid features.”

The corrected sentence appears below:

“As expected, the rates of CRs were higher in patients without baseline bone metastases, and in patients who had a prior nephrectomy. CR rates were similar irrespective of whether or not patients had baseline liver metastases.”

The Supplementary Table 1 has been updated directly in the original article.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.